<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636699</url>
  </required_header>
  <id_info>
    <org_study_id>PEPITES</org_study_id>
    <nct_id>NCT02636699</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy</brief_title>
  <acronym>PEPITES</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DBV Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DBV Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein&#xD;
      to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age&#xD;
      after a 12-month treatment by epicutaneous immunotherapy (EPIT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 18, 2017</completion_date>
  <primary_completion_date type="Actual">August 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population</measure>
    <time_frame>At Month 12</time_frame>
    <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening ED Subgroup</measure>
    <time_frame>At Month 12</time_frame>
    <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time</measure>
    <time_frame>Baseline and Months 3, 6 and 12</time_frame>
    <description>Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time</measure>
    <time_frame>Baseline and Months 3, 6 and 12</time_frame>
    <description>Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Viaskin Peanut 250mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viaskin Peanut 250mcg</intervention_name>
    <description>Peanut extract cutaneous patch</description>
    <arm_group_label>Viaskin Peanut 250mcg</arm_group_label>
    <other_name>DBV712</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Male or female children aged 4 through 11 years;&#xD;
&#xD;
          2. Physician-diagnosis of peanut allergy or children with a well documented medical&#xD;
             history of IgE-mediated symptoms after ingestion of peanut and currently following a&#xD;
             strict peanut-free diet, but without a physician diagnosis;&#xD;
&#xD;
          3. Peanut-specific IgE level (ImmunoCAP system) &gt;0.7 kU/L;&#xD;
&#xD;
          4. Positive peanut skin prick test (SPT) with a largest wheal diameter:&#xD;
&#xD;
               -  ≥6 mm for children 4 through 5 years of age at Visit 1,&#xD;
&#xD;
               -  ≥8 mm for children 6 years and above at Visit 1;&#xD;
&#xD;
          5. Positive DBPCFC at ≤300 mg peanut protein.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. History of severe anaphylaxis to peanut with any of the following symptoms:&#xD;
             hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or&#xD;
             incontinence);&#xD;
&#xD;
          2. Generalized dermatologic disease&#xD;
&#xD;
          3. Diagnosis of mast cell disorders, including mastocytosis or uricaria pigmentosa as&#xD;
             well as hereditary or idiopathic angioedema;&#xD;
&#xD;
          4. Diagnosis of asthma that fulfills any of the following criteria:&#xD;
&#xD;
               -  Uncontrolled persistent asthma as defined by National Asthma Education and&#xD;
                  Prevention Program Asthma guidelines 2007 or by Global Initiative for Asthma&#xD;
                  guidelines 2015,&#xD;
&#xD;
               -  Asthma treated with either a high daily high dose of inhaled corticosteroid or&#xD;
                  with a combination therapy of a medium or high daily dose of inhaled&#xD;
                  corticosteroid with a long acting inhaled β2 agonist or with a combination&#xD;
                  therapy of a high daily dose of inhaled corticosteroid with a long acting inhaled&#xD;
                  β2 agonist. Asthmatic subjects treated with a medium daily dose of inhaled&#xD;
                  corticosteroids are eligible. Intermittent asthmatic subjects who require&#xD;
                  intermittent use of inhaled corticosteroids for rescue are also eligible,&#xD;
&#xD;
               -  Two or more systemic corticosteroid courses for asthma in the past year or 1 oral&#xD;
                  corticosteroid course for asthma within 3 months prior to Visit 1, or during&#xD;
                  screening period,&#xD;
&#xD;
               -  Prior intubation/mechanical ventilation for asthma within 1 year prior to Visit&#xD;
                  1, or during screening;&#xD;
&#xD;
          5. Receiving β-blocking agents, angiotensin-converting enzyme inhibitors,&#xD;
             angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant&#xD;
             therapy;&#xD;
&#xD;
          6. Received anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or&#xD;
             any biologic immunomodulatory therapy within 1 year prior to Visit 1, during screening&#xD;
             period or during study participation;&#xD;
&#xD;
          7. Use of systemic long-acting corticosteroids within 12 weeks prior to Visit 1 and/or&#xD;
             use of systemic short-acting corticosteroids within 4 weeks prior to Visit 1 or during&#xD;
             screening;&#xD;
&#xD;
          8. Prior or concomitant history of any immunotherapy to any food;&#xD;
&#xD;
          9. Receiving or planning to receive any aeroallergen immunotherapy during their&#xD;
             participation in the study. Aeroallergen immunotherapy must be discontinued at the&#xD;
             time of Visit 1;&#xD;
&#xD;
         10. Any disorder in which epinephrine is contraindicated such as coronary artery disease,&#xD;
             uncontrolled hypertension, or serious ventricular arrhythmias.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Childrens' Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaffe Food Allergy Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina - Chapell Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASTHMA, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Medical</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Westmead</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheema Research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Allergy Asthma Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon Sussman Clinical Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM &amp; CHU Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Appliquée en Allergie de Québec (CRAAQ)</name>
      <address>
        <city>Quebec</city>
        <zip>QC G1V4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Hospital</name>
      <address>
        <city>Bonn</city>
        <zip>D-53115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigations Unit</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fleischer DM, Greenhawt M, Sussman G, Bégin P, Nowak-Wegrzyn A, Petroni D, Beyer K, Brown-Whitehorn T, Hebert J, Hourihane JO, Campbell DE, Leonard S, Chinthrajah RS, Pongracic JA, Jones SM, Lange L, Chong H, Green TD, Wood R, Cheema A, Prescott SL, Smith P, Yang W, Chan ES, Byrne A, Assa'ad A, Bird JA, Kim EH, Schneider L, Davis CM, Lanser BJ, Lambert R, Shreffler W. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019 Mar 12;321(10):946-955. doi: 10.1001/jama.2019.1113.</citation>
    <PMID>30794314</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenhawt M, Kim EH, Campbell DE, Green TD, Lambert R, Fleischer DM. Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3219-3221. doi: 10.1016/j.jaip.2020.05.030. Epub 2020 Jun 2.</citation>
    <PMID>32502548</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>September 17, 2021</results_first_submitted>
  <results_first_submitted_qc>September 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2021</results_first_posted>
  <disposition_first_submitted>February 28, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 28, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 5, 2019</disposition_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02636699/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02636699/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Phase III study was conducted in participants aged 4 to 11 years old with peanut allergy at 31 active centers in Australia, Canada, Germany, Ireland and USA. Participants were randomized in a 2:1 ratio to receive DBV712 250 micrograms (μg) (Viaskin® Peanut 250 μg) or placebo.</recruitment_details>
      <pre_assignment_details>Overall maximum study duration for each participant was approximately 61 weeks (6-week screening period, 53-week treatment period and 2-week follow-up period). At the first screening visit, participants underwent a double-blind, placebo-controlled food challenge (DBPCFC) up to a highest dose of 300 milligrams (mg) peanut protein to confirm their allergy and their entry peanut eliciting dose (ED).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DBV712 250 μg</title>
          <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with the investigational product (IP)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population was comprised of all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>DBV712 250 μg</title>
          <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="238"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="2.11"/>
                    <measurement group_id="B2" value="7.3" spread="2.30"/>
                    <measurement group_id="B3" value="7.3" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>4 to 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening ED Subgroup</title>
          <description>Screening ED Subgroup 1: participants with a screening ED of 1 mg, 3 mg or 10 mg peanut protein.&#xD;
Screening ED Subgroup 2: participants with a screening ED of 30 mg, 100 mg or 300 mg peanut protein.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Screening ED Subgroup 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Screening ED Subgroup 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population</title>
        <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.</description>
        <time_frame>At Month 12</time_frame>
        <population>The ITT population was comprised of all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV712 250 μg</title>
            <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall Population</title>
          <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population.</description>
          <population>The ITT population was comprised of all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="29.5" upper_limit="41.6"/>
                    <measurement group_id="O2" value="13.6" lower_limit="8.5" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of the difference in response rates between DBV712 250 μg group and Placebo group and 2-sided Newcombe 95% confidence interval (CI). P-value was obtained from a 2-sided 5% test to evaluate the null hypothesis of no difference in response rates between treatment groups using the Wald method. Clinical relevance was evaluated based on the lower bound of the Newcombe 95% CI of the difference in response rates ≥15%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald</method>
            <param_type>Difference in Response Rates (%)</param_type>
            <param_value>21.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.4</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening ED Subgroup</title>
        <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.</description>
        <time_frame>At Month 12</time_frame>
        <population>The ITT population was comprised of all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV712 250 μg</title>
            <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Percentages of Treatment Responders at Month 12; Analyzed in Each Screening ED Subgroup</title>
          <description>The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:&#xD;
ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or&#xD;
ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).&#xD;
Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup.</description>
          <population>The ITT population was comprised of all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening ED subgroup 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="25.7" upper_limit="54.3"/>
                    <measurement group_id="O2" value="20.0" lower_limit="8.1" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening ED subgroup 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="28.2" upper_limit="41.4"/>
                    <measurement group_id="O2" value="12.2" lower_limit="7.1" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Screening ED subgroup 1:&#xD;
Analysis of the difference in response rates between DBV712 250 μg group and Placebo group and 2-sided Newcombe 95% CI. P-value was obtained from a 2-sided 5% test to evaluate the null hypothesis of no difference in response rates between treatment groups using the Wald method. Clinical relevance was evaluated based on the lower bound of the Newcombe 95% CI of the difference in response rates &gt;0.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Wald</method>
            <param_type>Difference in Response Rates (%)</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>38.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Screening ED subgroup 2:&#xD;
Analysis of the difference in response rates between DBV712 250 μg group and Placebo group and 2-sided Newcombe 95% CI. P-value was obtained from a 2-sided 5% test to evaluate the null hypothesis of no difference in response rates between treatment groups using the Wald method. Clinical relevance was evaluated based on the lower bound of the Newcombe 95% CI of the difference in response rates &gt;0.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald</method>
            <param_type>Difference in Response Rates (%)</param_type>
            <param_value>22.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>30.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12</title>
        <description>The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>The ITT population was comprised of all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV712 250 μg</title>
            <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Reactive Dose (CRD) of Peanut Protein at Baseline and Month 12</title>
          <description>The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12.</description>
          <population>The ITT population was comprised of all participants who were randomized.</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.0" lower_limit="44.0" upper_limit="444.0"/>
                    <measurement group_id="O2" value="144.0" lower_limit="44.0" upper_limit="444.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444.0" lower_limit="144.0" upper_limit="1444.0"/>
                    <measurement group_id="O2" value="144.0" lower_limit="44.0" upper_limit="444.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment effect was estimated using the Hodges-Lehmann estimate of the difference in median CRDs at Month 12.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon rank-sum test</method>
            <param_type>Difference in Median CRD</param_type>
            <param_value>297.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>130.0</ci_lower_limit>
            <ci_upper_limit>317.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time</title>
        <description>Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
        <time_frame>Baseline and Months 3, 6 and 12</time_frame>
        <population>The ITT population was comprised of all participants who were randomized. Only those with non-missing data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV712 250 μg</title>
            <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Peanut-specific Immunoglobulin E (IgE) Over Time</title>
          <description>Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
          <population>The ITT population was comprised of all participants who were randomized. Only those with non-missing data were included in the analysis.</population>
          <units>Relative change (percentage)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.716" lower_limit="26.557" upper_limit="174.588"/>
                    <measurement group_id="O2" value="16.964" lower_limit="-12.591" upper_limit="48.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.716" lower_limit="-3.676" upper_limit="109.690"/>
                    <measurement group_id="O2" value="4.605" lower_limit="-26.380" upper_limit="30.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.858" lower_limit="-24.739" upper_limit="61.058"/>
                    <measurement group_id="O2" value="-6.919" lower_limit="-31.468" upper_limit="25.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time</title>
        <description>Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
        <time_frame>Baseline and Months 3, 6 and 12</time_frame>
        <population>The ITT population was comprised of all participants who were randomized. Only those with non-missing data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DBV712 250 μg</title>
            <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Changes From Baseline in Peanut-specific Immunoglobulin G4 Subtype (IgG4) Over Time</title>
          <description>Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline.</description>
          <population>The ITT population was comprised of all participants who were randomized. Only those with non-missing data were included in the analysis.</population>
          <units>Relative change (percentage)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.778" lower_limit="55.660" upper_limit="259.615"/>
                    <measurement group_id="O2" value="14.286" lower_limit="0.000" upper_limit="45.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.491" lower_limit="107.843" upper_limit="549.351"/>
                    <measurement group_id="O2" value="11.492" lower_limit="-9.677" upper_limit="42.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.487" lower_limit="196.458" upper_limit="1105.235"/>
                    <measurement group_id="O2" value="10.496" lower_limit="-10.108" upper_limit="33.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from Day 1, throughout the 53-week treatment period and additional 2-week follow-up period. Overall time frame of up to 55 weeks.</time_frame>
      <desc>The safety population was comprised of all participants who were randomized and received at least 1 dose of IP. Adverse events occurring after the end of the treatment period were recorded only if the Investigator considered there was a causal relationship with the IP and as such, were considered also as TEAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>DBV712 250 μg</title>
          <description>Participants applied 1 new DBV712 250 μg patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants applied 1 new placebo patch for 24 hours (±4 hours) every day for 12 months. The application duration was progressively increased to a duration of 24 hours daily over a 15-day period (6 hours during the first week, 12 hours during the second week and 24 hours from the third week onwards).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="42" subjects_affected="31" subjects_at_risk="238"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="238"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="48" subjects_at_risk="238"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="154" subjects_affected="83" subjects_at_risk="238"/>
                <counts group_id="E2" events="30" subjects_affected="14" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="118" subjects_affected="67" subjects_at_risk="238"/>
                <counts group_id="E2" events="54" subjects_affected="20" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site swelling</sub_title>
                <counts group_id="E1" events="86" subjects_affected="38" subjects_at_risk="238"/>
                <counts group_id="E2" events="18" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site eczema</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="238"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Application site urticaria</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="238"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="30" subjects_affected="20" subjects_at_risk="238"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" events="16" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="134" subjects_affected="73" subjects_at_risk="238"/>
                <counts group_id="E2" events="48" subjects_affected="30" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="82" subjects_affected="42" subjects_at_risk="238"/>
                <counts group_id="E2" events="40" subjects_affected="20" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="238"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="238"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="74" subjects_affected="39" subjects_at_risk="238"/>
                <counts group_id="E2" events="41" subjects_affected="18" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="97" subjects_affected="52" subjects_at_risk="238"/>
                <counts group_id="E2" events="27" subjects_affected="15" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="78" subjects_affected="30" subjects_at_risk="238"/>
                <counts group_id="E2" events="28" subjects_affected="16" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="50" subjects_affected="27" subjects_at_risk="238"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="238"/>
                <counts group_id="E2" events="31" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>DBV Technologies</organization>
      <phone>33-1-55-42-78-78</phone>
      <email>clinicaltrials@dbv-technologies.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

